In conclusion, these insights into the moonlighting activity of IDO1 within the TME provide potential explanations for the clinical failures observed in the IDO1 inhibitor trials and suggest more effective IDO1 targeting in cancer to neutralize both its enzymatic and non-enzymatic functions in the TME. Here, IDO1 is linked to cancer.